Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 4/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249190 | 1.00 | ADRB2 (0.45) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL8241987 | 0.98 | SLC6A3 (0.46) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL2769154 | 0.98 | SLC6A3 (0.46) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL4610367 | 0.81 | IDO1 (0.55) | METAP2METAP1 | |
| SCHEMBL19194749 | 0.77 | SLC6A2 (0.57) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL10528661 | 0.76 | SLC6A3 (0.54) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL8251822 | 0.75 | SLC6A4 (0.52) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL2771876 | 0.75 | SLC6A4 (0.52) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL7456086 | 0.75 | OPRM1 (0.45) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 | |
| SCHEMBL12261486 | 0.75 | SLC6A4 (0.59) | ADRB2SLC6A3SLC6A4SLC6A2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643989-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7132421-B2 | CIS-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1643989-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002575-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259867-A1 | CIS-imidazoles | TP53, MDM2, TP53BP1 | ADRB2 4435/4885SLC6A3 4530/4885SLC6A4 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.